CymitQuimica logo

CAS 1374744-69-0

:

Fedratinib dihydrochloride monohydrate

Description:
Fedratinib dihydrochloride monohydrate is a small molecule inhibitor primarily used in the treatment of certain hematological malignancies, particularly myelofibrosis. It functions as a selective inhibitor of Janus kinase 2 (JAK2), which plays a crucial role in the signaling pathways of various hematopoietic growth factors. The dihydrochloride form indicates the presence of two hydrochloride molecules associated with the compound, enhancing its solubility and stability in aqueous environments. The monohydrate designation signifies that one water molecule is included in the crystal structure, which can influence the compound's physical properties, such as solubility and stability. Fedratinib is characterized by its ability to modulate immune responses and has been studied for its efficacy in reducing splenomegaly and improving symptoms associated with myelofibrosis. As with many pharmacological agents, its use may be accompanied by side effects, necessitating careful monitoring during treatment. Overall, Fedratinib dihydrochloride monohydrate represents a significant advancement in targeted cancer therapies.
Synonyms:
  • CL121
  • N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide hydrochloride hydrate (1:2:1)
  • TG-101348
  • N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide hydrochloride hydrate
  • N-(tert-Butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide dihydrochloride hydrate
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 5 products.